

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application

Applicants : Leszek Wojnowski et al.
 Application No. : 10/070,588
 Confirmation No. : 7619
 Filed : March 8, 2002
 For : POLYMORPHISMS IN THE HUMAN hPXR GENE AND
 THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
 APPLICATIONS
 Group Art Unit : Not Yet Assigned
 Examiner : Not yet assigned

New York, New York
 March 25, 2003

Hon. Commissioner for Patents
 P.O. Box 2327
 Arlington, Virginia 22202

Attn: Box PCT

EXPRESS MAIL CERTIFICATION

Express Mail Label No. EK 708050316 US
 Date of Deposit: March 25, 2003

I hereby certify that this certification and the following papers:

1. a Response to a Notification of a Defective Response (in duplicate);
2. a Paper Copy of a Substitute Biochemical Sequence Listing;
3. a Computer Readable Form (CFR) of the Substitute Biochemical Sequence Listing;
4. Statements in Support of Computer Readable Form Submission under 37 C.F.R. §§ 1.821(f) and 37 C.F.R. § 1.821(g); and
5. a copy of the original Notification of a Defective Response.

are being deposited with the United States Postal Service, "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to Hon.

Commissioner for Patents, P.O. Box 2327, Arlington, Virginia
22202.

March 25, 2003

Name:

Lillian Garcia
Lillian Garcia

RECEIVED/PTO 25 MAR 2003

VOS-31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application

Applicants : Leszek Wojnowski et al.
Application No. : 10/070,588
Confirmation No. : 7619
Filed : March 8, 2002
For : POLYMORPHISMS IN THE HUMAN hPXR GENE AND
THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
APPLICATIONS
Group Art Unit : Not Yet Assigned
Examiner : Not yet assigned

New York, New York
March 25, 2003

Hon. Commissioner for Patents
P.O. Box 2327
Arlington, Virginia 22202

Attn: Box PCT

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] a Response to a Notification
of a Defective Response (in duplicate); [X] a Paper Copy of a
Substitute Biochemical Sequence Listing; [X] a Computer Readable
Form (CFR) of the Substitute Biochemical Sequence Listing; [X]
Statements in Support of Computer Readable Form Submission under
37 C.F.R. §§ 1.821(f) and 37 C.F.R. § 1.821(g); and [X] a copy of
the original Notification of a Defective Response.

EK708050316US

original Notification of a Defective Response.

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	-	* =	X	\$ = \$
INDEPENDENT CLAIMS	-	** =	X	\$ = \$
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM				+ \$ = \$

* If less than 20, insert 20.

TOTAL \$

** If less than 3, insert 3.

☐ A check in the amount of \$ in payment of the filing fee is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16 or 1.17, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

☐ Please charge \$ to Deposit Account No. 06-1075 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.


EXTENSION FEE

[] The following extension is applicable to the Response filed herewith; [] \$110.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.17(a)(1); [] \$400.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.17(a)(2); [] \$920.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.17(a)(3); [] \$1,440.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.17(a)(4); [] \$1,960.00 within fifth month pursuant to 37 C.F.R. § 1.17(a)(5).

[X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

The Director is authorized to charge any additional fees that may be due, or credit overpayment, to Deposit Account No. 06-1075. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Jane T. Gunnison (Reg. No. 38,479)
Attorneys for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

Rec'd PTO 25 MAR 2003

VOS-31

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application

Applicants : Leszek Wojnowski et al.
Application No. : 10/070,588
Confirmation No. : 7619
Filed : March 8, 2002
For : POLYMORPHISMS IN THE HUMAN hPXR GENE AND
THEIR USE IN DIAGNOSTIC AND THERAPEUTIC
APPLICATIONS
Group Art Unit : Not Yet Assigned
Examiner : Not yet assigned

New York, New York
March 25, 2003

Hon. Commissioner for Patents
P.O. Box 2327
Arlington, Virginia 22202

Attn: Box PCT

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Sir:

This is in response to the February 25, 2003
Notification of Defective Response, issued in the
above-identified application. In accordance with this
Notification of Defective Response applicants herewith submit:
a Response to a Notification of a Defective Response
(in duplicate);

EK708050316US

a Paper Copy of a Substitute Biochemical Sequence Listing;


a Computer Readable Form (CFR) of the Substitute Biochemical Sequence Listing; and

Statements in Support of Computer Readable Form Submission under 37 C.F.R. §§ 1.821(f) and 37 C.F.R. § 1.821(g).

A copy of the February 25, 2003 Notification of Defective Response is also enclosed.

The Director is hereby authorized to charge any additional fee that may be due, or to charge any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this Response is enclosed for that purpose.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Jane T. Gunnison (Reg. No. 38,479)

Attorneys for Applicants

Shawn-Marie Mayrand (Reg. No. 48,986)

Agent for Applicants

c/o FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box 101
 United States Patent and Trademark Office
 Washington, D.C. 20230
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/070,588	Leszek Wojnowski	VOS-31

INTERNATIONAL APPLICATION NO.

PCT/EP00/08827

I.A. FILING DATE	PRIORITY DATE
09/08/2000	09/10/1999

 1473
 FISH & NEAVE
 1251 AVENUE OF THE AMERICAS
 50TH FLOOR
 NEW YORK, NY 10020-1105

CONFIRMATION NO. 7619

371 FORMALITIES LETTER



OC00000009553746

Date Mailed: 02/25/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Request for Immediate Examination

RECEIVED

MAR 03 2003

 FISH & NEAVE - PATENT DEPT.
 REFERRED TO 371
 NOTED BY [Signature]

DOCUMENTED FOR

3/25/03
 NOT EXTENSIBLE

Applicant's response filed 10/15/2002 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 06/12/2002 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

EK708050316US

the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- Does not comply, Corrected diskette needed
- APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

PAULETTE R KIDWELL

Telephone: (703) 305-3656

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/070,588	PCT/EP00/08827	VOS-31